Voranigo: Uses, Dosage & Side Effects
A brain-penetrant dual IDH1/IDH2 inhibitor for the treatment of IDH-mutant grade 2 astrocytoma and oligodendroglioma in adults and adolescents
Voranigo (vorasidenib) is a targeted anticancer medication that inhibits mutant isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) enzymes. It is used for the treatment of grade 2 astrocytoma and oligodendroglioma in adults and adolescents aged 12 years and older (weighing at least 40 kg) who have undergone surgery alone and are not in immediate need of radiation therapy or chemotherapy. Voranigo is specifically designed to cross the blood-brain barrier and reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), thereby slowing or stopping the growth of IDH-mutant brain tumors. It is taken as a once-daily oral tablet and requires a prescription.
Quick Facts: Voranigo
Key Takeaways
- Voranigo (vorasidenib) is the first oral, brain-penetrant dual IDH1/IDH2 inhibitor approved for grade 2 IDH-mutant astrocytoma and oligodendroglioma, offering patients a targeted treatment option after surgery without the need for immediate radiation or chemotherapy.
- The drug works by blocking mutant IDH enzymes that overproduce the oncometabolite 2-hydroxyglutarate (2-HG), thereby slowing or halting the growth of brain tumors driven by IDH1 or IDH2 mutations.
- Liver function must be monitored before and during treatment, as elevated liver enzymes are the most common serious side effect; dose adjustments or treatment interruption may be necessary if hepatotoxicity occurs.
- Voranigo can reduce the effectiveness of hormonal contraceptives; women and men of reproductive potential must use effective contraception (including a barrier method if using hormonal contraceptives) during treatment and for at least 2 months after the last dose.
- The tablet must be taken on an empty stomach (no food for 2 hours before and 1 hour after) and swallowed whole; the recommended dose is 40 mg once daily for patients weighing 40 kg or more.
What Is Voranigo and What Is It Used For?
Voranigo is a targeted anticancer medication containing the active substance vorasidenib. It belongs to a new class of drugs known as isocitrate dehydrogenase (IDH) inhibitors, which represent a breakthrough in the treatment of certain types of brain tumors. Unlike traditional chemotherapy, which broadly attacks fast-dividing cells throughout the body, vorasidenib specifically targets the molecular abnormality that drives tumor growth in IDH-mutant gliomas.
The medication is approved for the treatment of grade 2 astrocytoma and oligodendroglioma in adults and adolescents aged 12 years and older, with a body weight of at least 40 kg, who have undergone surgical resection only and are not in immediate need of radiation therapy or chemotherapy. These are types of diffuse low-grade gliomas — slow-growing brain tumors that arise from the supportive glial cells of the central nervous system. While classified as low-grade, these tumors invariably progress over time and can transform into higher-grade malignancies, making effective early treatment critically important.
Voranigo is used only when the tumor cells harbor mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Before treatment begins, a laboratory test is performed on a sample of the tumor tissue (obtained during surgery) to confirm the presence of an IDH1 or IDH2 mutation. Approximately 70–80% of grade 2 and grade 3 gliomas carry IDH mutations, making this a common molecular feature in lower-grade brain tumors.
How Does Voranigo Work?
The IDH1 and IDH2 proteins play a vital role in cellular energy metabolism. Under normal conditions, these enzymes catalyze the conversion of isocitrate to alpha-ketoglutarate (α-KG) as part of the citric acid cycle (Krebs cycle). When the IDH1 or IDH2 gene is mutated, the resulting abnormal enzyme gains a new, harmful function: instead of producing α-KG, it converts α-KG into the oncometabolite 2-hydroxyglutarate (2-HG).
Elevated levels of 2-HG cause profound epigenetic changes within the cell. Specifically, 2-HG inhibits a family of enzymes called α-KG-dependent dioxygenases, which include histone demethylases and TET (ten-eleven translocation) enzymes involved in DNA demethylation. The resulting hypermethylation of DNA and histones leads to widespread alterations in gene expression, impaired cellular differentiation, and ultimately contributes to the development and progression of cancer. This epigenetic dysregulation is a hallmark of IDH-mutant gliomas.
Vorasidenib is specifically designed to cross the blood-brain barrier — a selective membrane that protects the brain from many substances circulating in the bloodstream. This is a critical advantage, as many drugs cannot reach effective concentrations within the brain. Once inside the brain, vorasidenib binds to and inhibits the mutant IDH1 and IDH2 enzymes, blocking the abnormal production of 2-HG. By reducing 2-HG levels, vorasidenib helps to reverse the epigenetic dysregulation driving tumor growth, thereby slowing or halting the progression of IDH-mutant gliomas.
The clinical efficacy of vorasidenib was demonstrated in the landmark INDIGO phase 3 randomized clinical trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent grade 2 IDH-mutant glioma following surgery alone. The trial also showed a significant delay in the time to next intervention (such as radiation or chemotherapy), providing patients with a longer period of preserved quality of life.
Voranigo is the first oral medication specifically designed to cross the blood-brain barrier and inhibit both mutant IDH1 and mutant IDH2 enzymes simultaneously. This dual inhibition is important because gliomas may harbor mutations in either IDH1 or IDH2, and vorasidenib provides coverage against both variants. The blood-brain barrier penetration sets vorasidenib apart from earlier IDH inhibitors that were primarily developed for blood cancers.
What Should You Know Before Taking Voranigo?
Contraindications
Before starting Voranigo, your healthcare provider needs to determine whether the medication is safe for you. There are specific situations in which Voranigo must not be used.
- Hypersensitivity: Do not take Voranigo if you are allergic to vorasidenib or any other ingredient in the formulation (including microcrystalline cellulose, croscarmellose sodium, silicified microcrystalline cellulose, magnesium stearate, sodium lauryl sulfate, hypromellose, titanium dioxide, lactose monohydrate, or macrogol).
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Voranigo if you have problems with your kidneys or if you have problems with your liver. Your healthcare team will assess whether the benefits of treatment outweigh the risks in your particular situation.
Voranigo can affect your liver function. Your doctor will perform blood tests to check your liver function before you start treatment and as needed during therapy. If liver enzyme elevations occur, your doctor may need to reduce the dose or temporarily or permanently discontinue treatment. Contact your doctor immediately if you experience yellowing of the skin or whites of the eyes (jaundice), dark or tea-colored urine, loss of appetite, pain in the upper right side of the abdomen, or a feeling of weakness or severe fatigue.
Elevated liver enzymes are the most common serious side effect associated with Voranigo. In clinical trials, increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported in a significant proportion of patients. Most elevations were grade 1 or 2 (mild to moderate) and were manageable with dose modifications or temporary interruption of therapy. However, more severe hepatotoxicity can occur, making regular monitoring essential throughout the course of treatment.
Pregnancy and Breastfeeding
Voranigo should not be used during pregnancy because it may harm the unborn child. If you are a woman who could become pregnant, your doctor will perform a pregnancy test before starting treatment. If you become pregnant while taking Voranigo, contact your doctor immediately.
Women who could become pregnant must use effective contraception during treatment and for at least 2 months after the last dose. Men whose partners could become pregnant must also use effective contraception during treatment and for at least 2 months after the last dose. Importantly, Voranigo can reduce the effectiveness of hormonal contraceptives (such as birth control pills, patches, or implants). If you or your partner uses a hormonal contraceptive, you must also use a barrier method (such as a condom or diaphragm) to prevent pregnancy.
It is unknown whether vorasidenib passes into breast milk. You should not breastfeed while taking Voranigo and for at least 2 months after the last dose. If you are breastfeeding, discuss alternative feeding options with your healthcare provider before starting treatment.
Voranigo may affect your ability to have children (fertility). If you are concerned about your fertility, speak with your doctor before starting treatment to discuss your options, which may include fertility preservation measures.
Children and Adolescents
Voranigo is approved for use in adolescents aged 12 years and older who weigh at least 40 kg. The safety and efficacy of Voranigo have not been established in children under 12 years of age, and it should not be given to this age group.
Special Populations
Voranigo is not expected to affect the ability to drive or use machines. However, some patients may experience dizziness or fatigue during treatment. If you experience these symptoms, use caution when driving or operating machinery until you know how the medication affects you.
The tablets contain lactose (a sugar found in milk and dairy products). If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The tablets also contain less than 1 mmol (23 mg) sodium per tablet, meaning they are essentially sodium-free.
How Does Voranigo Interact with Other Drugs?
Voranigo can interact with many other medications because it affects the body's drug-metabolizing enzyme systems, particularly the cytochrome P450 (CYP) pathway. It is essential to tell your doctor or pharmacist about all medications you are taking, have recently taken, or plan to take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Drugs That Increase Voranigo Levels
Certain medications can increase the concentration of vorasidenib in your blood, which may raise the risk of side effects. These drugs inhibit the enzymes that metabolize vorasidenib and include:
- Ciprofloxacin — an antibiotic used to treat bacterial infections
- Fluvoxamine — an antidepressant used to treat depression and obsessive-compulsive disorder
If you are taking either of these medications, your doctor may need to adjust your Voranigo dose or consider alternative treatments.
Drugs That Decrease Voranigo Effectiveness
Some medications can reduce the concentration of vorasidenib in your blood, potentially making it less effective at controlling your brain tumor. These drugs induce the enzymes that break down vorasidenib and include:
- Rifampicin — used to treat tuberculosis and certain other infections
- Phenytoin — used to treat epilepsy and seizures
Drugs Whose Effectiveness May Be Reduced by Voranigo
Voranigo is a CYP enzyme inducer, meaning it can accelerate the metabolism of many other drugs, reducing their blood levels and potentially making them less effective. The following table lists key medications affected by Voranigo:
| Medication | Category | Used For |
|---|---|---|
| Alfentanil | Anesthetic | Pain management during surgery |
| Carbamazepine, Fosphenytoin, Phenobarbital, Phenytoin | Antiepileptics | Seizures and epilepsy |
| Cyclosporine, Everolimus, Sirolimus, Tacrolimus | Immunosuppressants | Prevention of organ transplant rejection |
| Fentanyl | Opioid analgesic | Severe pain |
| Pimozide | Antipsychotic | Psychiatric conditions |
| Quinidine | Antiarrhythmic | Abnormal heart rhythm |
| Ibrutinib, Ifosfamide, Tamoxifen | Anticancer agents | Various cancers |
| Buspirone | Anxiolytic | Anxiety disorders |
| Darunavir, Saquinavir, Tipranavir | Antiretrovirals | HIV infection |
| Midazolam, Triazolam | Benzodiazepines | Sleep disorders, anxiety |
| Amitriptyline, Dosulepin, Imipramine, Trimipramine | Tricyclic antidepressants | Depression |
| Bupropion | Antidepressant / Smoking cessation aid | Depression, smoking cessation |
| Celecoxib | NSAID (COX-2 inhibitor) | Arthritis, pain, inflammation |
| Repaglinide | Antidiabetic | Type 2 diabetes |
| Rosuvastatin | Statin | High cholesterol |
| Valproic acid | Antiepileptic / Mood stabilizer | Epilepsy, bipolar disorder |
| Warfarin | Anticoagulant | Blood clot prevention |
| Hormonal contraceptives | Contraceptive | Pregnancy prevention |
This is not a complete list of all possible drug interactions. There may be additional medications that can interact with Voranigo beyond those listed here. Always consult your doctor or pharmacist before starting, stopping, or changing any medication while on Voranigo therapy.
Many patients with brain tumors take antiepileptic medications to control or prevent seizures. Several of these medications (including phenytoin, carbamazepine, phenobarbital, and valproic acid) interact with Voranigo. Your doctor may need to adjust the doses of your antiepileptic medications or switch to alternatives that do not interact with Voranigo. Never change or stop your antiepileptic medication without consulting your doctor.
What Is the Correct Dosage of Voranigo?
Always take Voranigo exactly as your doctor or pharmacist has told you. Do not change the dose or stop taking Voranigo without first talking to your doctor. The medication is taken by mouth (orally) once daily, and you should try to take it at the same time each day to maintain consistent drug levels in your body.
Adults and Adolescents (12 Years and Older)
Standard Dosage
Dose: 40 mg once daily (one 40 mg film-coated tablet)
Requirement: Body weight must be at least 40 kg
Route: Oral (by mouth)
Duration: Continue treatment for as long as directed by your doctor
Patients who weigh less than 40 kg should not take Voranigo, as appropriate dosing has not been established for this population. If you experience certain side effects during treatment, your doctor may need to reduce the dose, temporarily interrupt treatment, or permanently discontinue it.
How to Take Voranigo
Proper administration of Voranigo is essential for optimal drug absorption and effectiveness. Follow these important instructions:
- Take on an empty stomach: Do not eat any food for at least 2 hours before and 1 hour after taking the tablet. Food can affect the absorption of vorasidenib.
- Swallow the tablet whole: Take the tablet with a glass of water. Do not split, crush, or chew the tablet, as this may affect the dose you receive.
- Take at the same time each day: Consistency helps maintain stable drug levels in your body.
- If you vomit: Do not take an extra dose if you vomit after taking your tablet. Take your next scheduled dose at the regular time.
- Desiccant packet: Do not swallow the desiccant packet found inside the bottle. It is included to protect the tablets from moisture.
Dose Adjustments
Your doctor may adjust your dose based on how well you tolerate the medication. A lower dose of 10 mg once daily may be prescribed if you experience significant side effects, particularly liver enzyme elevations. The decision to modify the dose is based on the severity and persistence of the side effect and is made by your healthcare provider.
| Patient Group | Dose | Notes |
|---|---|---|
| Adults and adolescents ≥40 kg | 40 mg once daily | Standard recommended dose |
| Dose reduction (if needed) | 10 mg once daily | For management of side effects (e.g., liver enzyme elevations) |
| Patients <40 kg | Not recommended | Safety and dosing not established |
| Children under 12 years | Not recommended | Not studied in this age group |
Missed Dose
If you miss a dose of Voranigo, the action you should take depends on how much time has passed:
- Less than 6 hours late: Take the missed dose as soon as you remember, then take your next dose at the regular scheduled time.
- More than 6 hours late: Skip the missed dose entirely and take your next dose at the regular scheduled time.
Do not take a double dose to make up for a missed one. Try to set a daily reminder or alarm to help you remember to take your medication at the same time each day.
Overdose
If you accidentally take more tablets than prescribed, contact your doctor, pharmacist, or nurse immediately. You may need urgent medical attention. Keep the medication container with you so that healthcare professionals can identify what you have taken and how much.
Do not stop taking Voranigo unless your doctor tells you to. It is important to take Voranigo every day for as long as your doctor has prescribed it. Stopping treatment prematurely may allow the tumor to progress. If you have concerns about side effects or your treatment, discuss them with your healthcare team before making any changes.
What Are the Side Effects of Voranigo?
Like all medicines, Voranigo can cause side effects, although not everyone experiences them. The side effects listed below are based on clinical trial data and post-marketing surveillance. Your healthcare team will monitor you for these effects through regular clinical assessments and blood tests throughout your treatment.
Serious Side Effects
If you experience serious side effects, stop taking Voranigo and contact your doctor immediately. Your doctor may need to reduce the dose, pause treatment, or discontinue it entirely depending on the severity.
Contact your doctor right away if you notice yellowing of the skin or eyes, dark urine, loss of appetite, right-sided upper abdominal pain, or severe fatigue. These may be signs of serious liver damage that requires prompt medical evaluation.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Elevated liver enzymes in the blood (ALT, AST) — detected through routine blood tests
- Abdominal pain (stomach pain)
- Diarrhea
- Decreased platelet count (thrombocytopenia) — platelets help blood to clot; detected through blood tests; may lead to easy bleeding or bruising
- Fatigue (tiredness)
- Dizziness
Common
May affect up to 1 in 10 people
- Elevated blood sugar levels (hyperglycemia)
- Decreased appetite
- Low phosphate levels in the blood (hypophosphatemia) — detected through blood tests; may cause confusion or muscle weakness
- Shortness of breath (dyspnea)
- Gastroesophageal reflux disease (acid reflux) — a condition where stomach acid flows back into the esophagus
Managing Side Effects
Many of the side effects associated with Voranigo are manageable with appropriate medical care and monitoring. Your doctor will schedule regular blood tests to check your liver function, platelet count, blood sugar levels, and phosphate levels. Based on these results, adjustments to your treatment may be made.
Elevated liver enzymes are the most common laboratory abnormality. In most cases, these elevations are mild to moderate and resolve with dose reduction or temporary treatment interruption. Severe hepatotoxicity is less common but requires immediate medical attention. It is important to attend all scheduled blood test appointments so that any changes can be detected early.
For gastrointestinal side effects such as diarrhea and abdominal pain, your doctor may recommend dietary modifications or prescribe supportive medications. Fatigue is a common side effect that may be managed through appropriate rest, light physical activity, and energy conservation strategies. Dizziness should be reported to your doctor, especially if it affects your ability to drive or perform daily activities safely.
If you experience any side effects that concern you, or if a side effect becomes severe, contact your healthcare team. Even side effects not listed here should be reported, as they contribute to the ongoing monitoring of the medication's safety profile.
Reporting suspected side effects after a medicine has been authorized is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA's EudraVigilance system in the European Union).
How Should You Store Voranigo?
Proper storage of Voranigo is essential to maintain the effectiveness and safety of the medication. Follow these guidelines to ensure your medication remains in optimal condition:
- Keep out of reach: Store this medicine out of the sight and reach of children. The bottle has a child-resistant closure for added safety.
- Check expiry date: Do not use Voranigo after the expiry date printed on the bottle label and carton (after "EXP"). The expiry date refers to the last day of the stated month.
- Storage conditions: No special storage conditions are required. Store at room temperature in the original packaging.
- Desiccant: The bottle contains three desiccant containers. These are included to protect the tablets from moisture and must not be swallowed.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that you no longer use. These measures help protect the environment.
Voranigo is supplied in a plastic bottle with a child-resistant closure containing 30 film-coated tablets and three desiccant containers. The bottles are packed in cartons, with each carton containing one bottle.
What Does Voranigo Contain?
Understanding the composition of your medication can help you identify potential allergens or ingredients to which you may be sensitive. Below is a detailed breakdown of the active and inactive ingredients in Voranigo tablets.
Active Ingredient
The active substance is vorasidenib (as hemicitric acid, hemihydrate):
- Voranigo 10 mg: Each film-coated tablet contains 10 mg vorasidenib
- Voranigo 40 mg: Each film-coated tablet contains 40 mg vorasidenib
Inactive Ingredients (Excipients)
| Component | Ingredient | Function |
|---|---|---|
| Tablet core | Microcrystalline cellulose (E460) | Filler / Binder |
| Tablet core | Croscarmellose sodium | Disintegrant |
| Tablet core | Silicified microcrystalline cellulose | Filler / Flow agent |
| Tablet core | Magnesium stearate (E470b) | Lubricant |
| Tablet core | Sodium lauryl sulfate (E487) | Wetting agent |
| Film coating | Hypromellose | Film-forming agent |
| Film coating | Titanium dioxide (E171) | Opacifier / Colorant |
| Film coating | Lactose monohydrate | Filler |
| Film coating | Macrogol (E1521) | Plasticizer |
| Printing ink | Black iron oxide (E172) | Colorant |
| Printing ink | Propylene glycol (E1520) | Solvent |
| Printing ink | Hypromellose (E464) | Film-forming agent |
Tablet Appearance
- 10 mg tablets: White to off-white, round film-coated tablets, debossed with "10" on one side
- 40 mg tablets: White to off-white, oblong film-coated tablets, debossed with "40" on one side
Voranigo is manufactured by Servier (Ireland) Industries Ltd., Gorey Road, Arklow, Co. Wicklow, Ireland, and marketed by Les Laboratoires Servier, Suresnes, France.
Frequently Asked Questions About Voranigo
Voranigo (vorasidenib) is used to treat IDH-mutant grade 2 astrocytoma and oligodendroglioma in adults and adolescents aged 12 years and older (weighing at least 40 kg) who have undergone surgery only and do not immediately require radiation therapy or chemotherapy. It specifically targets tumors with IDH1 or IDH2 mutations and works by blocking the abnormal IDH enzymes to slow or stop tumor growth.
Voranigo contains vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes. When these genes are mutated, the IDH enzymes produce excessive amounts of 2-hydroxyglutarate (2-HG), an oncometabolite that drives tumor development. Vorasidenib crosses the blood-brain barrier and blocks these abnormal enzymes, reducing 2-HG levels and thereby slowing or halting glioma growth.
No, Voranigo should not be used during pregnancy as it may harm the unborn child. Women who could become pregnant must use effective non-hormonal contraception (or hormonal contraception plus a barrier method) during treatment and for at least 2 months after the last dose. Men with partners who could become pregnant must also use effective contraception during the same period. Importantly, Voranigo can reduce the effectiveness of hormonal contraceptives, so a barrier method must always be used in addition.
Yes, Voranigo can reduce the effectiveness of hormonal contraceptives such as birth control pills, patches, and implants. This is because vorasidenib induces certain liver enzymes (CYP enzymes) that accelerate the breakdown of hormonal contraceptives. If you or your partner uses a hormonal contraceptive, you must also use a barrier method (such as condoms or a diaphragm) to prevent pregnancy during treatment and for at least 2 months after the last dose.
If you miss a dose by less than 6 hours, take it as soon as you remember and then continue with your regular schedule. If more than 6 hours have passed since your scheduled dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a missed one.
Voranigo must be taken on an empty stomach (no food for at least 2 hours before and 1 hour after) because food can affect how the drug is absorbed into your body. Eating around the time of dosing may alter the amount of vorasidenib that reaches your bloodstream, potentially reducing its effectiveness or changing its safety profile. Following the fasting instructions ensures consistent and optimal drug absorption.
References
- European Medicines Agency (EMA). Voranigo (vorasidenib) — Summary of Product Characteristics. 2025. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). VORANIGO (vorasidenib) — Prescribing Information. 2024.
- Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589–601. doi:10.1056/NEJMoa2304194
- Wen PY, Packer RJ. The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021;23(8):1215–1217.
- European Association of Neuro-Oncology (EANO). Guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Lancet Oncol. 2024.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2025.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023.
- Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608.
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
- British National Formulary (BNF). Vorasidenib. National Institute for Health and Care Excellence (NICE). 2025.
Editorial Team
Medical Content Team
Specialist physicians in neuro-oncology and clinical pharmacology with extensive experience in brain tumor research and treatment
Medical Review Board
Independent panel of board-certified physicians who review all content according to WHO, EMA, FDA, NCCN, and EANO guidelines
Pharmacology Advisors
Clinical pharmacologists specializing in oncology therapeutics and drug interaction assessment
Accessibility Team
WCAG 2.2 AAA compliance specialists ensuring content is accessible to all users including those with disabilities
All medical content is reviewed according to the iMedic Editorial Standards, following the GRADE evidence framework and international clinical guidelines. Content is updated regularly to reflect the latest medical evidence and regulatory information.